Participants will be asked to report the numbers of times they have used the substance in the past month.
| Group | Value | 95% CI |
|---|---|---|
| Intervention | 0.83 | ± 2.12 |
| Attention-Placebo Control | 1.03 | ± 2.26 |
Last reviewed · How we verify
Preventing Drug Abuse Among Sexual Minority Youth
NA trial testing Free2b in Substance Abuse in 1,216 participants. Completed in 30 March 2024.
| Lead sponsor | Columbia University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 1,216 |
| Start date | 15 January 2020 |
| Primary completion | 30 March 2024 |
| Estimated completion | 30 March 2024 |
| Sites | 1 location across United States |
Columbia University
Adults 15 to 17, any sex, with Substance Abuse. Patients with the condition only — healthy volunteers not accepted.
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Participants will be asked to report the numbers of times they have used the substance in the past month.
| Group | Value | 95% CI |
|---|---|---|
| Intervention | 0.83 | ± 2.12 |
| Attention-Placebo Control | 1.03 | ± 2.26 |
Participants will be asked to report the numbers of times they have used the substance in the past month.
| Group | Value | 95% CI |
|---|---|---|
| Intervention | 1.22 | ± 2.49 |
| Attention-Placebo Control | 1.37 | ± 2.64 |
Participants will be asked to report the numbers of times they have used the substance in the past month.
| Group | Value | 95% CI |
|---|---|---|
| Intervention | 1.93 | ± 3.91 |
| Attention-Placebo Control | 2.30 | ± 4.74 |
Participants will be asked to report the numbers of times they have used the substance in the past month.
| Group | Value | 95% CI |
|---|---|---|
| Intervention | 2.49 | ± 4.86 |
| Attention-Placebo Control | 2.67 | ± 5.72 |
Participants will be asked to report the numbers of times they have used the substance in the past month.
| Group | Value | 95% CI |
|---|---|---|
| Intervention | 0.18 | ± 0.88 |
| Attention-Placebo Control | 0.25 | ± 0.97 |
Participants will be asked to report the numbers of times they have used the substance in the past month.
| Group | Value | 95% CI |
|---|---|---|
| Intervention | 0.35 | ± 1.05 |
| Attention-Placebo Control | 0.32 | ± 0.97 |
Participants will be asked to report the numbers of times they have used the substance in the past month.
| Group | Value | 95% CI |
|---|---|---|
| Intervention | 0.50 | ± 1.38 |
| Attention-Placebo Control | 0.59 | ± 1.60 |
Participants will be asked to report the numbers of times they have used the substance in the past month.
| Group | Value | 95% CI |
|---|---|---|
| Intervention | 0.65 | ± 1.64 |
| Attention-Placebo Control | 0.78 | ± 2.41 |
Participants will be asked to report the numbers of times they have used the substance in the past month.
| Group | Value | 95% CI |
|---|---|---|
| Intervention | 0.31 | ± 3.23 |
| Attention-Placebo Control | 0.39 | ± 4.29 |
Participants will be asked to report the numbers of times they have used the substance in the past month.
| Group | Value | 95% CI |
|---|---|---|
| Intervention | 0.50 | ± 4.11 |
| Attention-Placebo Control | 0.48 | ± 3.74 |
Participants will be asked to report the numbers of times they have used the substance in the past month.
| Group | Value | 95% CI |
|---|---|---|
| Intervention | 0.70 | ± 5.23 |
| Attention-Placebo Control | 0.79 | ± 5.67 |
Participants will be asked to report the numbers of times they have used the substance in the past month.
| Group | Value | 95% CI |
|---|---|---|
| Intervention | 0.76 | ± 5.27 |
| Attention-Placebo Control | 1.05 | ± 6.61 |
The planned randomized clinical trial will longitudinally test a tailored, web-based drug abuse prevention program with a nationwide sample of 15- to 17-year-old sexual minority youth (youth who identify as gay, lesbian, bisexual, or unsure of their sexual orientation).
1 peer-reviewed publication reference this trial (live from Europe PMC):
Verify or expand the search:
Currently open trials in the same condition.
Trials by the same sponsor.
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03954535.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing